<DOC>
	<DOCNO>NCT00631358</DOCNO>
	<brief_summary>The primary purpose study quantify change expression biomarkers ocular surface Sjogren 's Syndrome participant treatment Maxidex .</brief_summary>
	<brief_title>Assessment Inflammatory Biomarkers Expressed Sjogren 's Population : Effect Topical Steroid Intervention</brief_title>
	<detailed_description />
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria Sjorgren 's Population : 17 year old LogMar visual acuity 0.6 good Ocular inflammation associate Sjogren 's Syndrome Has adverse reaction either topical systemic steroid past Has diabetes ( type 1 2 ) Has glaucoma evidence ocular hypertension either eye treatment either within six month Visit 1 Has wear contact lenses within one week prior Visit 1 Has receive ocular prescription therapy last 30 day Has active ocular infection inflammation associate Sjogren 's Syndrome . Has find vitreous , macula , retina choroid show sign inflammation and/or structural change opinion investigator consider abnormal unstable participant</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Ocular inflammation</keyword>
</DOC>